论文部分内容阅读
目的观察万适宁对小儿下感的疗效、安全性及对免疫功能的影响。方法将确诊的90例9个月～14岁的LRRI随机分为万适宁组60例和迪塞组30例,分别根据病情和年龄口服万适宁。由专人观察记录两组疗效及万适宁组的毒副作用和免疫学变化。结果万适宁组治疗后患儿CD3+、CD4+和CD4+/CD8+及IgG和IgA均显著升高。肝肾功及心肌酶等均无异常改变。结论万适宁对小儿下感疗效优于迪塞,并可显著改善免疫功能,未见明显毒副作用。
Objective To observe the effect, safety and immune function of Wanningning on pediatric lower respiratory tract infection. Methods Ninety LRRs of 90 patients aged 9 months to 14 years were randomly divided into 60 cases of Wanningning group and 30 cases of Degui group, and were given Wankanning according to their condition and age respectively. Observed by hand to record the two groups of efficacy and Wanning Ning toxic side effects and immunological changes. Results Wanning Ning group after treatment CD3 +, CD4 + and CD4 + / CD8 + and IgG and IgA were significantly increased. Liver and kidney function and myocardial enzymes were no abnormal changes. Conclusions Wanningning is superior to Decai in treating pediatric lower exacerbation, and can significantly improve immune function with no obvious side effects.